Pear CEO Sees Fulfilment And Reimbursement Challenges Ahead
Executive Summary
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.
You may also be interested in...
Minute Insight: Pear Gets FDA’s STeP Designation For Chronic Pain Therapeutic
Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.
Minute Insight: Pear Therapeutics Inks Agreement With SoftBank To Develop Japan-Focused Digital Therapeutic
Pear Therapeutics signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.
Pear Adds Spanish Version Of Its Addiction Therapy PDTs
Availability of Spanish-language prescription digital therapeutics for the treatment of substance use disorder and opioid use disorder will address important health equity and health care disparities, according to Pear.